Oneova 5 Tablet contains Letrozole 5 mg, a non-steroidal aromatase inhibitor used primarily in the treatment of hormone receptor-positive breast cancer in postmenopausal women. By inhibiting the aromatase enzyme, Letrozole effectively reduces estrogen production, which is essential for the growth of certain types of breast tumors. This medication is commonly prescribed as adjuvant therapy following surgery or radiation, as well as for advanced or metastatic breast cancer. Letrozole is also utilized off-label for ovulation induction in women with anovulatory infertility. The recommended dosage and duration of treatment depend on the clinical condition and physician’s assessment. Patients should be monitored regularly for therapeutic response and potential adverse effects, which may include hot flashes, joint pain, fatigue, and osteoporosis due to estrogen depletion. Caution is advised in patients with hepatic impairment, and it is contraindicated during pregnancy and lactation. Oneova 5 Tablet should be taken orally with or without food, preferably at the same time each day to maintain consistent blood levels. Patients are encouraged to report any unusual symptoms or side effects to their healthcare provider promptly. Proper adherence to prescribed therapy is crucial for optimal clinical outcomes.